ABSTRACT
Neurocryptococcosis is a fungal illness with high mortality and represents the second most common infection of the central nervous system in patients with acquired immunodefi ciency syndrome (AIDS). The incidence of the infection caused by Cryptococcus in patients with AIDS is related to other factors beyond a low level of the cluster of differentiation 4 (CD4) T-cell counts and the fungal exposure.
Cryptococcus neoformans is the etiologic agent of cryptococcosis, a major opportunistic infection in patients with impaired cellular immune response, especially those with AIDS and diabetes mellitus. C. neoformans capsule is considered as the major virulence factor of this intracellular pathogen. The polysaccharide capsule antigen contributes to the virulence by being antiphagocytic among other features that affect the host immune response 1, 2 . Cryptococcal meningitis treatment has been primarily focused on optimizing antifungal therapy based on amphotericin B plus fl ucytosine or fl uconazole. However, elevated intracranial pressure is an important risk factor for high mortality in this opportunistic infection in immunosuppressed patients, especially those with human immunodefi ciency virus/acquired immunodefi ciency syndrome (HIV/AIDS) disease 1 . In this study, we evaluate, retrospectively, the benefi ts of ventriculoperitoneal (VP) shunting in order to improve the survival rate of patients with uncontrollable intracranial hypertension (ICH) associated with cryptococcal meningitis.
We retrospectively analyzed the epidemiological (age, gender, risk factors for HIV infection), clinical, microbiological, and immunological characteristics, and clinical outcomes of 15 patients who developed cryptococcal meningitis and presented symptoms consistent with ICH including headache, altered mental status, meningism, and neurosensory changes. Clinical and neurological examinations were performed on all patients. To evaluate the infl ammatory response to the fungal infection, all samples of cerebrospinal fl uid (CSF) were analyzed for white blood cell counts, glucose, and protein levels. Direct examination with India ink stain and cultures on Sabouraud dextrose agar and brain-hart infusion agar were also performed. Before lumbar puncture, a head computed tomography (CT) scan was done in all cases. CD4 T cell counts were taken from all patients with HIV. Elevated intracranial pressure was defi ned as ≥ 25cm H 2 O of CSF during lumbar puncture. Patients with persistent elevated spinal pressure following frequent lumbar puncture drainage and having undergone 2 weeks of cumulative amphotericin B deoxycholate therapy with or without fl uconazole underwent a VP shunt (Medtronic ® ), despite positive CSF cultures for C. neoformans. Differentiation of the encapsulated yeast, C. neoformans, was performed using the creatine-dextrose-bromothymol-blue-thymine (CDBT) Table 1 . All patients were seronegative for hepatitis C virus (HCV) infection. Headache and fever were present in all patients. In the 14 HIV seropositive patients, the median of CD4 T cell count at the time of neurocryptococcosis diagnosis was 50 cells/μL (range, 6-511 cells/µL). At baseline, all CSF samples were macroscopically clear. All patients had an opening pressure higher than 25cm H 2 O, with a median of 42cm H 2 O (range, 26-50cm H 2 O). The median glucorrachia level was 40mg/dL (range, 11-70mg/ dL). Mean CSF protein levels was 1.0g/dL with a median of 0.67mg/dL (range, 0.28-2.74mg/dL). Median leukocyte count in CSF was 55 cells/μL (range, 1-690cells/μL), most of which were lymphocytes and monocytes. Direct examination of CSF with India ink smear was positive in 75% of patients; cultures were positive in 100% of them. C. neoformans var. grubii was identifi ed in all cases in which the CDBT test was performed.
Before surgical procedure, the patients began antifungal therapy based on amphotericin B deoxycholate alone or in combination with fl uconazole and continued with the frequent high-volume lumbar puncture if they were neurologically symptomatic. At preoperative time, the median opening pressure was 42cm H 2 O (range, 15-65cm H 2 0). Preoperative cultures of CSF were positive in 50% of patients. Polysaccharide cryptococcal capsular antigen in CSF was positive in all cases, with a median titer of 1/1,000 (range, 1/10 to 1/5,000). Serum polysaccharide cryptococcal capsular antigen was also positive in all of the patients, with a median titer of 1/550 (range, 1/10 to 1/10,000).
All patients underwent implantation of CSF shunts; 14 patients received VP shunts and one other was treated with a lumbar-peritoneal derivation. Twelve patients had good clinical outcomes; three presented complications related to the neurosurgical procedure. This included sepsis with meningitis and multiorgan failure in one of the patients who died, postoperative bacterial meningitis with a good response to antibiotic therapy, and a large abdominal multiseptated pseudocyst which required the VP shunt removal. Patients who had complications related to the surgical procedure were excluded from the postoperative analysis. One month after surgery, considered as the postoperative period, CSF median aperture pressure was sharply reduced in the 12 patients, with a median of 14.5cm H 2 O (range: 10 to 20cm H 2 O) and only two (16%) patients persisted with positive CSF cultures. All biochemical and microbiological parameters of the CSF were also modifi ed in these patients, with a dramatical reduction in the indirect signs of cryptococcal infection (antigenorrachia and antigenemia titers) and infl ammatory response. Glucorrachia was not modifi ed after VPS and showed a median of 41mg/ dL (range, 38-85mg/dL). Median cell counts decreased to 3.5 cells/μL (range, 1-40 cells/μL), while proteinorrachia slightly increased as expected owing to the neurosurgery itself, with a median of 0.89g/dL (range, 0.33-2.6g/dL). Polysaccharide cryptococcal capsular antigen in CSF was positive in 90% of cases, with a median titer of 1/550 (range, 1/10 to 1/1,000). Serum polysaccharide cryptococcal capsular antigen was also positive in 90% of patients, with a median titer of 1/100 (range, 0 to 1/10,000). Even though the small sample size precludes an optimal statistical analysis of these fi ndings, median CSF aperture pressure was signifi cantly reduced (p < 0.01). Microbiological data for baseline, preoperative, and one month postoperative are summarized in Table 2 . Neurosensory sequelae were frequent in patients and included different grades of visual loss (including blindness) in six and hearing loss in two. Mean complete dose of amphotericin B after surgery was 3,000mg; median complete dose was 1,880mg (range, 250 -5,650mg). Higher doses were not associated with better outcome of neurosensory sequelae or postsurgical complications. After a minimum of one year of follow up, 12 patients were still alive and negative for C. neoformans upon microbiological examination of CSF.
Cryptococcal meningitis is one of the most common fungal infections in AIDS patients. The treatment of this opportunistic infection remains sub-optimal in many settings. Among patients with AIDS, the rate of infection ranges from 23% to 48.6% and neurocryptococcosis is the most frequent clinical manifestation of the disease in 70% to 90% of all the cases 2, 3 . Patients with AIDS having cryptococcal meningitis differ from non-HIVinfected subjects with the same infection in that they present very little infl ammatory response in CSF, large fungal burden, and few mass lesions.
The most severe complication of this opportunistic disease is the uncontrollable ICH. Uncontrollable ICH due to cryptococcal meningitis in patients with AIDS plays an important role in morbidity and mortality 14 . In a recent study, Souza et al.
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reported a high crytococcal meningoencephalitis-related mortality (48.4%) in Brazil. The pathophysiology of ICH in these patients is poorly understood. Fries and colleagues 4 , suggest that strain-specifi c characteristics can infl uence in the development of ICH in an experimental model of rats with cryptococcal meningoencephalitis. The authors found that phenotypic variants of C. neoformans (smooth and mucoid) differed in their abilities to promote ICH. In their experimental study, rats infected with the mucoid variant develop ICH whereas rats infected with the smooth phenotype did not. These results correlated with a short survival and a higher CSF fungal burden in mucoid variant-infected rats. In addition, higher levels of polysaccharide accumulated in the CSF and brain of mucoid variant-infected rats were detected. These fi ndings were also associated with a more pronounced but ineffective infl ammatory response in the meninges of mucoid-variant of C. neoformans.
The mechanisms underlying ICH in patients with cryptococcal meningitis include increased vascular permeability and cerebral edema associated with cytokine-induced infl ammation and the clogging of the arachnoid villi with cryptococci and the consecutive impairment of their resorptive function 4 . Beside these, C. neoformans also has several virulence factors such as urease, mannitol, and inositol, which have been implicated in increasing brain edema and CSF osmolarity 4 .
In a large and prospective clinical trial, Graybill and colleagues 5 demonstrated that higher CSF opening pressure at baseline was correlated with higher cryptococcal capsular polysaccharide antigen titers, a higher frequency of positive India ink smear results, and a higher frequency of headache and neurological compromise. In addition, patients with ICH had a shorter life span than those who had baseline-opening pressures < 250mm H 2 O.
Different studies suggest that the opening pressure should be measured at the fi rst lumbar puncture in all patients with suspected cryptococcal meningitis. In those with elevated intracranial pressure, additional lumbar punctures, including daily lumbar punctures, should be performed until the pressure is adequately controlled 6 . Pharmacological agents such as mannitol and corticosteroids are generally avoided, and neurological interventions, including VP or ventriculoatrial shunts placement, are generally delayed or avoided 7 .
Among patients with uncontrollable ICH, the best time to implant a permanent shunt (VP or ventriculoatrial) is controversial, but generally, the device must be placed after the initiation of an optimal antifungal therapy 7 .
Mechanical drainage of CSF is a part of managing ICH in cryptococcal meningitis associated with AIDS. Some authors describe important sequelae, probably related to the ischemia resulting from ICH 8 . Serial lumbar punctures are a common practice among infectologists and clinicians for the management of these patients. As a secondary choice, some clinicians prefer to place a lumbar drainage, which has a high risk of infection or malfunction 8 . The need for permanent VP shunting after 4 weeks of appropriate antifungal therapy is often necessary in patients who require serial lumbar punctures 9 .
CSF culture is one of the methods to predict the clinical outcome in these patients. Robinson and colleagues 10 suggest that a positive CSF culture for C. neoformans after 2 weeks of antifungal therapy is associated with a poor clinical outcome in comparison with a negative result. Elevated intracranial pressure is another signifi cant and predictive factor for morbidity and mortality in patients with HIV-associated cryptococcal meningitis 9 . Patients who present high intracranial pressure that persist despite antifungal therapy based on amphotericin B plus fl uconazole or fl ucytosine, have a high risk of serious sequelae and mortality rates. These patients include those who do not respond adequately to antifungal therapy, remain with high CSF pressure levels, and have persistent neurological symptoms despite frequent lumbar punctures 10 . They should be considered for CSF shunting at an early stage of the disease.
ICH is associated with serious complications in patients with cryptococcal meningitis and can be adequately treated with the placement of a VP shunt, even in those cases where the neuroimaging studies do not reveal hydrocephalus and those of persistent CSF cryptococcal infection 11, 12 .
Although the medical management of ICH in these patients is discussed, the placement of a VP shunt should be the primary therapeutic alternative 13 . However, post-surgical meningitis and ventriculitis from shunt infection are well-documented complications in these patients. Both complications frequently occur in the early postoperative stage and are secondary to wound infection or intraoperative contamination. Acute visceral perforation leading to peritonitis by the abdominal portion of VP shunt is a rare but severe complication of this procedure. Another possible complication is the formation of loculated intraperitoneal pseudocysts with infected or sterile CSF that are associated with abdominal, gastrointestinal, or genitourinary symptoms. It is generally assumed that device implantation on a non-sterile medium may be associated with clinical progression and device infection. However, clinical conditions and potential or established complications, like ICH, may still be considered for device implantation. In a risk versus benefi ts assessment, VP shunts may be useful in selected patients independent of the persistence of cryptococcal infection, in order to prevent sequelae or to optimize the management of intracranial pressure. In this regard, in our study that includes immunocompromised patients, we identifi ed only three complications associated with the surgical procedure.
There are obvious limitations to this study, including its retrospective nature and the obvious absence of a control group. The small size of the cohort and the participation of a single center of infectious diseases are other limitations.
In conclusion, patients who do not benefi t from antifungal therapy alone, remain with high CSF pressure levels, and continue with neurological symptoms despite frequent lumbar punctures, must be considered for VP placement. In particular, VP placement must be considered in those who present serious visual loss or ocular palsies, even in cases of persistent CSF cryptococcal infection. Early diagnosis and shunt placement are essential to improve the poor survival rate and the neurological functions in these critically ill patients.
